SEC Form 4 · accession 0001209191-16-155300
REATA PHARMACEUTICALS INC · RETA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Edward Bass
Director
Period of report
Dec 14, 2016
Accepted (ET)
Dec 15, 2016 · 11:02 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A common stockF1 | Dec 14, 2016 | P | 5,000 | $21.76 | A | 30,585 | D | |
| Class A common stock | holding | — | — | — | 3,455 | I | By Bass Family Trust A | |
| Class A common stock | holding | — | — | — | 1,448 | I | By Bass Trust FBO James E. Bass |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on one day at prices ranging from $21.73 to $21.96, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.